Date: 2012-03-07
Type of information: Production agreement
Compound: Light Path™ Discovery Services
Company: Lonza (Switzerland) LegoChem Biosciences (South Korea)
Therapeutic area: Technology - Services
Type agreement: R&D
production
manufacturing
Action mechanism:
Disease:
Details: Lonza has concluded an agreement with Korean Biotech, LegoChem Biosciences, for the custom material production of a monoclonal antibody that will be used for in vivo proof of concept studies for their technology platform development. Under this agreement, Lonza will produce pre-clinical material using Light Path™ Discovery Services at its applied protein services facility in Cambridge, UK.
Lonza’s Light Path™ Custom Material Services supports projects in their early phase, providing cGMP product within 11 months. In addition, Lonza’s Light Path™ Discovery Service provides non GMP product in 6 to 10 weeks, to support customers in the discovery testing phase. Since the launch of Light Path™ in early 2011, Lonza has seen an increased demand for this unique offering focused on a reduced timeline to IND filing. Light Path™ allows customers to reach their clinical milestones more efficiently.
Financial terms:
Latest news:
